Premium
Potential role of coenzyme Q 10 in facilitating recovery from statin‐induced rhabdomyolysis
Author(s) -
Wang L. W.,
Jabbour A.,
Hayward C. S.,
Furlong T. J.,
Girgis L.,
Macdonald P. S.,
Keogh A. M.
Publication year - 2015
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.12712
Subject(s) - rhabdomyolysis , statin , medicine , coenzyme a , pharmacology , biochemistry , enzyme , chemistry , reductase
Rhabdomyolysis is a rare, but serious complication of statin therapy, and represents the most severe end of the spectrum of statin‐induced myotoxicity. We report a case where coenzyme Q 10 facilitated recovery from statin‐induced rhabdomyolysis and acute renal failure, which had initially persisted despite statin cessation and haemodialysis. This observation is biologically plausible due to the recognised importance of coenzyme Q 10 in mitochondrial bioenergetics within myocytes, and the fact that statins inhibit farnesyl pyrophosphate production, a biochemical step crucial for coenzyme Q 10 synthesis. Coenzyme Q 10 is generally well tolerated, and may potentially benefit patients with statin‐induced rhabdomyolysis.